Subscribe
Be the first with the news that moves the market- Imugene (IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments for lung cancer
- The parties will evaluate the safety and efficacy of Imugene’s PD1-Vaxx, a B-cell activating immunotherapy, in combination with atezolizumab
- The phase 1b trial will be undertaken in the US and Australia and will determine the safety and efficacy of the treatment
- Earlier today, Imugene was granted a European patent for its HER-Vaxx immunotherapy technology, which is designed to treat cancer
- On the market, Imugene was up 5.26 per cent and is trading at 30 cents per share
Imugene (IMU) has signed a clinical trial supply agreement with Roche to evaluate the combination of treatments for lung cancer.
The parties will evaluate the safety and efficacy of Imugene’s PD1-Vaxx, a B-cell activating immunotherapy, in combination with atezolizumab, an immune checkpoint inhibitor targeting PD-L1.
The combined treatment is for patients with non-small cell lung cancer (NSCLC).
The phase 1b trial will be undertaken in the US and Australia and will determine the safety, efficacy as either first-line therapy in ICI treatment-naïve NSCLC patients or ICI pretreated patients.
Under the five year agreement, Imugene will be the sponsor of the study and will fund the clinical study from existing budgets and resources. Meanwhile, Roche will supply atezolizumab for the duration of the study.
Notably, Tecentriq has previously shown clinically meaningful benefits in various types of lung cancer, with six currently approved indications in the US.
Additionally, it was the first approved cancer immunotherapy for adjuvant NSCLC and also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer in combination with chemotherapy.
“It’s an outstanding accomplishment to see Imugene collaborate with Roche, in combination with our PD1-Vaxx drug,” CEO and Managing Director Leslie Chong said.
“PD1-Vaxx has shown a tolerable safety profile and encouraging efficacy in patients with
NSCLC, and we are looking forward to evaluating PD1-Vaxx with atezolizumab in ICI treatment-naïve and pretreated NSCLC patients.”
Earlier today, Imugene was granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer.
On the market, Imugene was up 5.26 per cent and is trading at 30 cents per share at 12:55 pm AEDT.
